SLN Silence Therapeutics Plc

TIDMSLN

RNS Number : 4927K

Silence Therapeutics PLC

22 September 2016

22 September 2016

Notice of Results

London, 22 September 2016 - Silence Therapeutics plc, AIM:SLN ("Silence" or the "the Company") a leader in the discovery, delivery and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, will announce results for the six months ending 30 June 2016 on Tuesday 27 September 2016.

 
 Silence Therapeutics plc               Tel: +44 (0)20 3457 6900 
 Ali Mortazavi, Chief Executive 
  Officer 
 David Ellam, Chief Financial 
  Officer 
 
 Canaccord Genuity Limited              Tel: +44 (0)20 7523 8350 
  (Nominated Adviser and 
  Joint Broker) 
 Dr Julian Feneley/Henry 
  Fitzgerald-O'Connor/Emma 
  Gabriel 
 
 Peel Hunt LLP (Joint Broker)           Tel: +44 (0)20 7418 8900 
 James Steel/Oliver Jackson 
 
 Media Enquiries:                       Tel: +44 (0) 20 3727 1000 
 FTI Consulting 
 Simon Conway/Brett Pollard/Stephanie 
  Cuthbert 
 

Notes to Editors

About Silence Therapeutics plc

Our technology harnesses the body's natural mechanisms to create therapeutic effects within its cells. This technology can selectively silence or replace any gene in the genome, modulating gene expression up as well as down in a variety of organs and cell types, in vivo. We have developed proprietary modifications to improve the robustness of RNA sequences, as well as advanced chemistries to enhance the effective delivery of therapeutic RNA molecules to target cells.

This information is provided by RNS

The company news service from the London Stock Exchange

END

NORGMGZLVMNGVZM

(END) Dow Jones Newswires

September 22, 2016 02:01 ET (06:01 GMT)

Silence Therapeutics (LSE:SLN)
Historical Stock Chart
From Apr 2024 to May 2024

Silence Therapeutics (LSE:SLN)
Historical Stock Chart
From May 2023 to May 2024